Vir Biotechnology, Inc.

VIRSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1706431

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$86.2M	$1.6B	—	—	—
Cost of Revenue	$2.8M	$146.3M	$65.9M	$0.00	$0.00
Research and Development Expense	$579.7M	$474.6M	$448.0M	$302.4M	$148.5M
Selling, General and Administrative Expense	$174.4M	$161.8M	$160.8M	$70.9M	$37.6M
Operating Expenses	—	—	—	—	—
Operating Income (Loss)	-$684.3M	$833.1M	$420.8M	-$297.0M	-$178.0M
Nonoperating Income (Expense)	$56.1M	-$78.8M	$129.1M	-$1.6M	-$3.5M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$1.4B	$1.9B	$2.8B	$2.0B	$918.8M
Assets, Current	$1.0B	$1.6B	$2.5B	$1.6B	$772.4M
Cash and Cash Equivalents, at Carrying Value	$241.6M	$848.6M	$347.8M	$436.6M	$109.3M
Accounts Receivable, after Allowance for Credit Loss, Current	—	—	—	$773.1M	$0.00
Liabilities	$248.4M	$328.8M	$724.1M	$522.4M	$201.9M
Liabilities, Current	$119.7M	$175.4M	$511.0M	$341.2M	$99.1M
Accounts Payable, Current	$5.1M	$6.3M	$6.4M	$6.5M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$778.8M	$1.7B	-$47.6M	-$190.9M	-$129.6M
Net Cash Provided by (Used in) Investing Activities	$164.6M	-$1.2B	-$140.8M	-$9.9M	-$256.2M
Net Cash Provided by (Used in) Financing Activities	$7.5M	$34.8M	$100.3M	$529.5M	$449.2M
Payments to Acquire Property, Plant, and Equipment	$21.6M	$68.0M	$21.8M	$6.5M	$8.9M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)